Associate Professor Alexandre CHAN


Department of Pharmacy, National University of Singapore
18 Science Drive 4, Singapore 117543
Tel: +65 6516 7814
Fax: +65 6779 1554

Teaching Activities in NUS

  • PR 4102 Pharmacotherapy 3
  • PR 4103 Research Methodology
  • PR 4104 Pharmacy Practice 3
  • PR 5110 Clinical Pharmacokinetics and Therapeutic Drug Monitoring
  • PR 5131 Advanced Pharmacotherapy 2
  • PR 5132 Advanced Pharmacotherapy 3
  • PR 5136 PharmD Seminar

Professional Appointments

  • Associate Professor (Tenured) and Deputy Head (Clinical), Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
  • Specialist Pharmacist (Oncology Pharmacy), Department of Pharmacy, National Cancer Centre Singapore, Singapore
  • Assistant Clinical Professor, Department of Clinical Pharmacy, University of California San Francisco, USA
  • Adjunct Professor, Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific, USA

Other Appointments

  • Master of Public Health, 2011, Department of Epidemiology and Public Health, National University of Singapore (Singapore)
  • PGY-2 Oncology Specialty Residency, 2005 – 2006, Department of Pharmaceutical Services, University of California Davis Medical Center (USA)
  • PGY-1 Pharmacy Practice Residency, 2004 – 2005, Department of Clinical Pharmacy, University of California San Francisco (USA)
  • Doctor of Pharmacy (Pharm.D., Highest Honors), 2004, Ernest Mario School of Pharmacy, Rutgers University (USA)
  • The Steven M. Grunberg Memorial Award, Multinational Association of Supportive Care in Cancer (MASCC)
  • Fellowship in the American College of Clinical Pharmacy (FCCP)
  • Board Certified Pharmacotherapy Specialist (BCPS), Board of Pharmaceutical Specialties
  • Board Certified Oncology Pharmacist (BCOP), Board of Pharmaceutical Specialties
  • Registered Pharmacist in Singapore, New Jersey (USA), California (USA) and Macau
  • Young Scientist Award, Faculty of Science, National University of Singapore
  • The Ernest Little Award, Rutgers University
  • Members of Rho Chi and Phi Lambda Sigma

Media Publicity on Clinical Practice and Research

  • Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WK, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol 2015; doi:10.1093/neuonc/nov162 (IF=6.776)
  • Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan G, Tan YP, Yong WS, Madhukumar P, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, Chan A. Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study. Ann Oncol 2015;26(7):1446-51 (IF=7.04)
  • Teo YL, Wee HL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestion of toxicities from sunitinib in Asian patients. Pharmacogenomics Journal 2015. Epub DOI: 10.1038/tpj.2015.13 (IF=4.229)
  • Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. European Journal of Cancer 2015; 51(4):437-450 (IF=4.819)
  • Ng T, Khor CC, Ho HK, Chan A. The Genetic Variants Underlying Breast Cancer Treatment-Induced Chronic and Late Toxicities: A Systematic Review. Cancer Treatment Reviews 2014; 40(10):1199-1214. (IF=6.024)
    Chan A, Lees J, Keefe D. The Changing Paradigm for Supportive Care in Cancer Patients. Support Care Cancer 2014;22(6):1441-5. (IF=2.65)
  • Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, Preetha M, Ooi WS, Chay WY, Dent R, Ang SF, Lo SK, Yap YS, Ng R, Chan A. Evaluated Minimal Clinically Important Difference in Perceived Cognitive Disturbances among Patients with Breast Cancer. J Clin Epidemiology 2014; pii: S0895-4356(14)00005-5. (IF=5.332)
  • Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treatment Review 2013; 39(2):199-206. (IF=6.024)
  • Chan A, Shih V, Chiang J, Chew L, Tay K, Quek R, Tao M, Lim ST. Clinical pharmacy services and research for lymphoma patients at a cancer center. J Onc Pharm Pract 2013; 19(1): 24-30.
  • Cheung YT, Shwe M, Tan YP, Fan G, Ng R, Chan A. Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. Ann Oncol 2012; 23(10):2547-52. (IF=7.38)
  • Chan A, Tang T, Ng T, Shih V, Tay K, Quek R, Tao M, Lim ST. To SMILE or not: Supportive Care Matters. J Clin Oncol 2012; 30 (9): 1015-6. (IF=18.37)
  • Lee J, Chan A. Polypharmacy in the elderly cancer patient: clinical implications and management. Lancet Oncology 2011;12(13):1249-5 (IF=25.12)
  • Ng TRD, Chan A. Dosing recommendations of targeted cancer therapies in patients with special needs: Evidence and Controversies. Crit Rev Oncol Hematol 2012; 81: 58-74. (IF=4.637)

Full listing available from PubMed